Global Markets for Treatments of Dementia and MovementDisorders -- Focus on Movement DisordersReport Details:Published:Sep...
through 2017.Applications for syndromes of dementia and movement disorder treatments, or therapeutictechnologies, are also...
METHODOLOGYBCC conducted a comprehensive literature search, which included technical newsletters andjournals, and many oth...
REGULATORY DEVELOPMENTS AFFECTING SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDER PRODUCTSChapter- 5: NEW DEVELOPMENTS 19Table ...
ACORDA THERAPEUTICS INC.ACTAVIS ELIZABETHAFFIRIS AGALLIANCE PHARMA PLCALLON THERAPEUTICS INC.ALPHAPHARMALZHYME LTD.AMERICA...
HAMELN PHARMACEUTICALS LTD.HELICON THERAPEUTICS INC.HOSPIRA INC.INTELLECT NEUROSCIENCES INC.INTRA-CELLULAR THERAPIES INC.J...
TAKEDA PHARMACEUTICAL CO. LTD.TERCICA INC.TEVA PHARMACEUTICAL INDUSTRIES LTD.TORRENT PHARMAUCB SAUDL LABORATORIESUPSHER-SM...
DEMENTIA AND MOVEMENT DISORDERS BY REGION, THROUGH 2017Table 14 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYND...
TO TREAT HALLERVORDEN-SPATZ DISEASE, 2011Table 35 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA ANDMOVEMENT ...
Figure 9 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY DISEASE TYPE, 2010-2017Figure 10 : GL...
Contact: sales@reportsandreports.com for more information.
Upcoming SlideShare
Loading in …5
×

Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Movement Disorders

225 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
225
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Movement Disorders

  1. 1. Global Markets for Treatments of Dementia and MovementDisorders -- Focus on Movement DisordersReport Details:Published:September 2012No. of Pages: 172Price: Single User License – US$3900•The global market for treatments for syndromes of dementia and movement disorders was valued at $10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.•Treatments for movement disorders are expected to be worth $3.2 billion in 2012 and $4.8 billion in 2017, a CAGR of 8.3%.•Sales of Parkinson’s drugs used to treat movement disorder syndromes are expected to have a value of $2.9 billion in 2012 and nearly $4.3 billion in 2017, a CAGR of 8.1%REPORT SCOPEINTRODUCTIONSTUDY OBJECTIVESBCC’s goal in conducting this study is to provide an overview of the current and futurecharacteristics of the global markets for treatments for syndromes of dementia and movementdisorders. The key objective is to present a comprehensive analysis and the future direction of themarket as it shapes drug and therapy development.This report explores present and future strategies within the neurodegenerative disorder market,which includes treatments and therapies for progressive dementia, progressive dementia withother neurological abnormalities and movement disorders. Market gains, setbacks and needs arediscussed in this report. Comparisons, usage and the advantages and disadvantages of differenttypes of technologies, including small molecules and monoclonal antibodies, are also presented inthis report.A detailed analysis of the structure of the syndromes of dementia and movement disorder industryhas been conducted. Revenues are broken down by neurodegenerative disease and primaryclinical/pathological feature. Sales figures are estimated for the five-year period from 2012
  2. 2. through 2017.Applications for syndromes of dementia and movement disorder treatments, or therapeutictechnologies, are also discussed separately in the report, with an emphasis on small molecule andmonoclonal antibodies technology. The report also covers significant patents and their allotmentin each category.REASONS FOR DOING THIS STUDYExtensive research in the field of syndromes of dementia and movement disorders and companycollaborations with research institutes have highlighted the importance of understanding the natureof these disorders. New technological developments are providing disease-modifying therapiesfor the late stages of the disorders. Collaborations between research institutes and pharmaceuticalcompanies are on the rise as state-of-the-art technology is being explored to develop moreefficient products and therapies.R&D spending, along with increasing competition, patent expiries and new technologies are takingthe market in a new direction. Global market revenues increased from 2009 to 2011 and areexpected to continue to show growth over the forecast period as new advances, launches andcollaborations continue to influence the market. This study looks at most of the systems affectedby these factors.Acquisition strategies and collaborations by companies are also covered in this report. This studyalso discusses the strength and weaknesses of each type of technology in light of the newtechnologies, growing competition and changing customer needs.CONTRIBUTIONS OF THE STUDY AND FOR WHOMThis study contributes to the areas of market growth in treatments for Alzheimer’s disease, Lewybody dementia, Pick’s disease, Huntington’s disease, corticobasal ganglionic degeneration,Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease. Pharmaceutical biotechnical companies, research institutes and physicians willfind this study to be of interest.SCOPE OF THE STUDYThe scope of this study encompasses the neurodegenerative disorders in the pharmaceutical andbiotechnology markets. BCC analyzes each market and its applications, regulatory environment,technology involved, market projections and market share. Technological issues include the latesttrends and developments. The emerging market for enzyme inhibitors includes countries such asIndia, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and Mexico.
  3. 3. METHODOLOGYBCC conducted a comprehensive literature search, which included technical newsletters andjournals, and many other sources. Data were collected through interviews and correspondencewith manufacturers of enzyme inhibitors’ technical experts. Projections were based on estimatessuch as the current number of end users, potential end users, mergers and acquisitions, andmarket trends.Get your copy of this report @http://www.reportsnreports.com/reports/195542-global-markets-for-treatments-of-dementia-and-movement-disorders-focus-on-movement-disorders.htmlMajor points covered in Table of Contents of this report includeTable Of ContentsChapter- 1: INTRODUCTION - Complimentary 3STUDY OBJECTIVESREASONS FOR DOING THIS STUDYCONTRIBUTIONS OF THE STUDY AND FOR WHOMSCOPE OF THE STUDYMETHODOLOGYINFORMATION SOURCESABOUT THE AUTHORRELATED BCC RESEARCH REPORTSBCC ONLINE SERVICESDISCLAIMERChapter- 2: EXECUTIVE SUMMARY 2Table Summary : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, THROUGH 2017Figure Summary : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2010-2017Chapter- 3: OVERVIEW 10THE BRAINCLASSIFICATION OF NEURODEGENERATIVE DISORDERSNEURODEGENERATIVE DISORDERSDIAGNOSTIC TESTS FOR NEURODEGENERATIVE DISORDERSChapter- 4: REGULATORY ASPECTS 6INTRODUCTIONDRUG APPROVALS
  4. 4. REGULATORY DEVELOPMENTS AFFECTING SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDER PRODUCTSChapter- 5: NEW DEVELOPMENTS 19Table 6 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2012Table 7 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2011Table 8 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2010Chapter- 6: GLOBAL MARKETS 13MARKETS BY CLINICAL/PATHOLOGICAL FEATUREMARKET BY DISEASE TYPEMARKET BY REGIONMARKETS BY TECHNOLOGYChapter- 7: MARKET FOR MOVEMENT DISORDER SYNDROMES 34MARKET BY TYPE OF DISEASEMARKETS BY REGIONREGIONAL MARKETS BY DISEASE TYPEMARKET BY TECHNOLOGYINDUSTRY STRUCTUREChapter- 8: PATENT ANALYSIS 20PATENTS ISSUED BY YEARPATENTS BY DISEASE CATEGORYPATENTS BY DISEASE TYPEPATENTS BY COUNTRYPATENTS BY COMPANYChapter- 9: CURRENT SITUATION 7MARKET TRENDSOVERALL DRIVERS OF THE MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERSOTHER FACTORS AFFECTING THE MARKETCOLLABORATIONS/MERGERS AND ACQUISITIONSChapter- 10: COMPANY PROFILES 55ABBOTT LABORATORIESABLYNX NVACCERA INC.
  5. 5. ACORDA THERAPEUTICS INC.ACTAVIS ELIZABETHAFFIRIS AGALLIANCE PHARMA PLCALLON THERAPEUTICS INC.ALPHAPHARMALZHYME LTD.AMERICAN REGENT INC.APOTEX INC.APOTHECA INC.ASTELLAS PHARMA INC.ASTRAZENECA GMBHAUROBINDO PHARMA LTD.BAXTER INTERNATIONAL INC.BELLUS HEALTH INC.BOEHRINGER INGELHEIM LTD.BRISTOL-MYERS SQUIBBBRYANT RANCH PREPACKCADILA HEALTHCARE LTD.CARACO PHARMACEUTICAL LABORATORIESCARDINAL HEALTHCELLZOME AGCIPLA LTD.COGNITION THERAPEUTICS INC.COLUCID PHARMACEUTICALS INC.COMENTIS INC.CORTEX PHARMACEUTICALSCYTOS BIOTECHNOLOGY AGDAIICHI SANKYO CO. LTD.DR. REDDYS LABORATORIES LTD.EISAI CO. LTD.ELAN PHARMA INTERNATIONAL LTD.ELI LILLY AND CO.ENDO PHARMACEUTICALS INC.ENVIVO PHARMACEUTICALSEVOTEC AGEPITOMICS INC.EXONHIT THERAPEUTICS SAFOREST LABORATORIES INC.GLAXOSMITHKLINE PLCGLENMARK GENERICS LTD.H. LUNDBECK A/S
  6. 6. HAMELN PHARMACEUTICALS LTD.HELICON THERAPEUTICS INC.HOSPIRA INC.INTELLECT NEUROSCIENCES INC.INTRA-CELLULAR THERAPIES INC.JAZZ PHARMACEUTICALS PLCMAJOR PHARMACEUTICALSMEDIVATION INC.MEMORY PHARMACEUTICALS CORP.MERCK SERONOMERCK SHARP & DOHME LTD.MERZ PHARMA GMBH & CO KGAAMITHRIDION INC.MYLAN PHARMACEUTICALSNEUREN PHARMACEUTICALS LTD.NEURO-HITECH INC.NEUROPTIX CORP.NEUROSEARCH A/SNEWRON PHARMACEUTICALS SPANOSCIRA SANOVARTIS AGNYMOX PHARMACEUTICAL CORP.ORCHID CHEMICALS & PHARMACEUTICALS LTD.ORION CORP.ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC.PAR PHARMACEUTICALSPERRIGO CO.PFIZER INC.PHARNEXTPHYSICIANS TOTAL CARE INC.PLIVA HRVATSKA D.O.O.PRASCO LABORATORIESRANBAXY LABORATORIES LTD.ROCHE HOLDING LTD.ROXANE LABORATORIES INC.SANDOZ INTERNATIONAL GMBHSANOFISANTHERA PHARMACEUTICALSSHIONOGI & CO.STADA ARZNEIMITTEL AGSUN PHARMATAJ PHARMACEUTICALS LTD.
  7. 7. TAKEDA PHARMACEUTICAL CO. LTD.TERCICA INC.TEVA PHARMACEUTICAL INDUSTRIES LTD.TORRENT PHARMAUCB SAUDL LABORATORIESUPSHER-SMITH LABORATORIESVALEANT PHARMACEUTICALSVERNALIS PLCWATSON PHARMACEUTICALS INC.WEST-WARD PHARMACEUTICALChapter- 11: APPENDIX I: ABBREVIATIONS 3List of TablesSummary Table : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, THROUGH 2017Table 1 : CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERSBY PRIMARY CLINICAL/PATHOLOGICAL FEATURETable 2 : ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012Table 3 : PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERSTable 4 : FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012Table 5 : FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDERS, 2010 TO MARCH 2012Table 6 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2012Table 7 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2011Table 8 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2010Table 9 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017Table 10 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREATNEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011Table 11 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJORNEURODEGENERATIVE DISORDERS, THROUGH 2017Table 12 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011Table 13 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
  8. 8. DEMENTIA AND MOVEMENT DISORDERS BY REGION, THROUGH 2017Table 14 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011Table 15 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017Table 16 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011Table 17 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY DISEASE TYPE, THROUGH 2017Table 18 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENTDISORDER SYNDROMES BY DISEASE TYPE, 2011Table 19 : GLOBAL SALES OF DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY REGION, THROUGH 2017Table 20 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENTDISORDER SYNDROMES BY REGION, 2011Table 21 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON’S DISEASEBY REGION, THROUGH 2017Table 22 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEMATROPHY BY REGION, THROUGH 2017Table 23 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVESUPRANUCLEAR PALSY BY REGION, THROUGH 2017Table 24 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZDISEASE BY REGION, THROUGH 2017Table 25 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY TECHNOLOGY, THROUGH 2017Table 26 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENTDISORDER SYNDROMES BY TECHNOLOGY, 2011Table 27 : LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TOTREAT PARKINSONS DISEASETable 28 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USEDTO TREAT PARKINSON’S DISEASE, 2011Table 29 : LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TOTREAT MULTIPLE SYSTEM ATROPHYTable 30 : MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USEDTO TREAT MULTIPLE SYSTEM ATROPHY, 2011Table 31 : LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TOTREAT PROGRESSIVE SUPRANUCLEAR PALSYTable 32 : MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USEDTO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011Table 33 : LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TOTREAT HALLERVORDEN-SPATZ DISEASETable 34 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED
  9. 9. TO TREAT HALLERVORDEN-SPATZ DISEASE, 2011Table 35 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDERS ISSUED PER YEAR, 2010—MARCH 2012Table 36 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012Table 37 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA(PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012Table 38 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY DISEASE TYPE, 2010-MARCH 2012Table 39 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA(PROGRESSIVE DEMENTIA) BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012Table 40 : U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIABY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012Table 41 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012Table 42 : U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012Table 43 : NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OFDEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012Table 44 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY COMPANY, 2010-MARCH 2012List of FiguresSummary Figure : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2010-2017Figure 1 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS, 2010-2017Figure 2 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREATNEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011Figure 3 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJORNEURODEGENERATIVE DISORDERS, 2010-2017Figure 4 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011Figure 5 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS BY REGION, 2010-2017Figure 6 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011Figure 7 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017Figure 8 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011
  10. 10. Figure 9 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY DISEASE TYPE, 2010-2017Figure 10 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENTDISORDER SYNDROMES BY DISEASE TYPE, 2011Figure 11 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY REGION, 2010-2017Figure 12 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENTDISORDER SYNDROMES BY REGION, 2011Figure 13 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON’S DISEASEBY REGION, 2010-2017Figure 14 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEMATROPHY BY REGION, 2010-2017Figure 15 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVESUPRANUCLEAR PALSY BY REGION, 2010-2017Figure 16 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE BY REGION, 2010-2017Figure 17 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY TECHNOLOGY, 2010-2017Figure 18 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENTDISORDER SYNDROMES BY TECHNOLOGY, 2011Figure 19 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USEDTO TREAT PARKINSON’S DISEASE, 2011Figure 20 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USEDTO TREAT MULTIPLE SYSTEM ATROPHY, 2011Figure 21 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USEDTO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011Figure 22 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USEDTO TREAT HALLERVORDEN-SPATZ DISEASE, 2011Figure 23 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012Figure 24 : PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012Figure 25 : PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012Figure 26 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BYCLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012*Figure 27 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY DISEASE TYPE, 2010-MARCH 2012Figure 28 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA(PROGRESSIVE DEMENTIA) BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012Figure 29 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012
  11. 11. Contact: sales@reportsandreports.com for more information.

×